Last gasp pro-generics shift from government enrages Italian pharma
This article was originally published in Scrip
A "drastic measure" that "hits at the heart of the pharmaceutical industry in Italy" has been sneaked through in an eleventh-hour late-night amendment to the comprehensive Spending Review legislation, Farmindustria, the industry association, has warned. Assogenerici, the Italian association of generic pharmaceutical companies, on the other hand, has applauded the provision, saying it could enable major savings in public health spending.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.